University of Helsinki researchers have introduced a groundbreaking molecule, TriSb92, administered nasally, proving effective against diseases caused by all known SARS-CoV-2 variants. This molecule is poised to be a vital tool in halting the transmission and spread of the virus, particularly in anticipation of future pandemics.
In laboratory animal studies, TriSb92 demonstrated robust protection against coronavirus infection by targeting a region in the spike protein common to all current variants, inhibiting its functionality. Administered nasally, the molecule effectively prevents infection even after a few hours of exposure, distinguishing itself from face masks. Postdoctoral Researcher Anna R. Mäkelä from Professor Kalle Saksela’s research group notes that TriSb92 also includes protection against the latest variants, such as XBB, BF7, and BQ.1.1.
Continue reading… “Nasal Spray Breakthrough: University of Helsinki Researchers Develop Molecule Effective Against All SARS-CoV-2 Variants”